Thymosin Alpha-1 (10 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (Thymosin Alpha-1, 10 mg each):
  • 8 weeks: approximately 3 vials required (26.6 mg total)
  • 12 weeks: approximately 5 vials required (40.6 mg total)
  • 16 weeks: approximately 6 vials required (54.6 mg total)
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 9 mL — 1 bottle required (10 mL each)
  • 12 weeks (5 vials): 15 mL — 2 bottles required (10 mL each)
  • 16 weeks (6 vials): 18 mL — 2 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

Thymosin Alpha-1 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
• Typical daily range: 300–500 mcg once daily (gradual titration).
• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate and follow product-specific use-by instructions.

Thymosin Alpha-1 (Tα1) is a 28–amino acid peptide originally isolated from the thymus gland, recognized for its broad immunomodulatory properties^[1]. It has been investigated as an immune enhancer in chronic viral infections (hepatitis B/C, HIV/AIDS) and critical illness (sepsis, COVID-19)^[2][3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

The 10 mg vial is a strength and calculation input, not a clinical dose. With the page’s retained 3.0 mL reconstitution, the concentration is approximately 3.33 mg/mL.

• Vial contents: 10 mg of Thymosin Alpha-1 (Tα1), also called thymalfasin.
• Final volume: 3.0 mL of bacteriostatic water.
• Concentration: 10 mg ÷ 3.0 mL = approximately 3.33 mg/mL.
• U-100 conversion: 1 unit = 0.01 mL = approximately 33.3 mcg at this concentration.
• Chart calculations: 300 mcg = 9 units (0.09 mL); 500 mcg = 15 units (0.15 mL).

Published human studies have used different doses, frequencies, durations, populations, and formulations. Those study schedules should not be treated as interchangeable with the educational calculation schedule above.^[1][12]

This page translates the retained protocol amounts into syringe markings for a 10 mg vial.

• Mass and volume: Always confirm the prescribed or study amount first, then convert that mass to mL using the actual vial concentration.
• U-100 markings: Syringe units describe liquid volume, not peptide international units.
• Small-volume accuracy: Match syringe capacity to the measured volume; measurement error can increase when only a small fraction of a syringe is filled.^[8]
• Strength comparison: A 10 mg vial lasts longer than a 5 mg vial at the same amount per administration, but vial strength alone does not determine an appropriate research amount.

Storage conditions depend on the specific product and preparation.

• Follow the current product label, lot documentation, and laboratory stability instructions.
• Keep the vial protected from light and avoid unnecessary temperature cycling.
• Use aseptic technique, record the preparation date, and do not infer a universal beyond-use date from vial strength or bacteriostatic water alone.
• Do not use a preparation that is cloudy, discolored, contaminated, or otherwise inconsistent with its product instructions.

Thymosin Alpha-1 is a 28-amino-acid peptide derived from prothymosin alpha. The synthetic form is commonly called thymalfasin. Research has examined its immunomodulatory activity in infectious disease, critical illness, cancer adjunct settings, and vaccine-response studies, but findings depend on the population and study design.^[1][5]

Mechanistic studies describe effects on dendritic cells, T-cell maturation and signaling, natural killer cells, toll-like receptor pathways, and cytokine regulation. These biological observations do not establish a general-purpose treatment dose or prove benefit for an otherwise healthy person.^[2][6]

Human research does not use one universal Thymosin Alpha-1 dosage protocol. Examples include 1.6 mg subcutaneously twice weekly in chronic hepatitis B trials, condition-specific schedules in liver-failure research, and every-12-hour administration for seven days in a modern sepsis trial.^{[4][15][17][12]}

The large 2025 TESTS phase 3 trial enrolled 1,106 adults with sepsis and found no clear reduction in 28-day all-cause mortality compared with placebo. This result is important context because earlier smaller studies and meta-analyses sometimes reported favorable signals.^[12][3]

For chronic viral disease, older randomized trials evaluated thymalfasin in defined patient populations and treatment periods. Those regimens were disease-specific clinical research, not validation of the retained page schedule for general use.^[4][15]

Reviews describe Thymosin Alpha-1 as an immune-response modulator rather than a simple immune stimulant. Laboratory and clinical literature discusses dendritic-cell maturation, T-cell differentiation, natural-killer-cell activity, pattern-recognition signaling, and context-dependent cytokine effects.^[1][2][6]

The direction and clinical significance of these effects can vary by disease state. Mechanistic plausibility is not the same as proof of clinical efficacy, which is why controlled outcomes should carry more weight than isolated pathway findings.^[12]

The literature uses several names for the same 28-amino-acid molecule, including Thymosin alpha 1, Thymosin alpha1, Thymosin α1, Tα1, thymalfasin, and the brand name Zadaxin. It is the synthetic form of thymosin alpha-1 first characterized from thymosin fraction 5, rather than the separate peptide thymosin beta-4.^[1][5]

Clinical trial and clinical studies terminology also requires context. Researchers may measure immune response, immune function, peripheral blood lymphocytes, dendritic cell activity, natural killer cells, Th1-associated cytokine signaling, inflammatory response, vaccine-adjuvant outcomes, or a disease-specific response rate. A change in an immune-cell marker does not automatically establish safety and efficacy, a direct antiviral effect, or a benefit in clinical practice.^[2][6][12]

A small crossover study in healthy volunteers evaluated three subcutaneous formulations. Mean time to maximum concentration was approximately one to two hours, the reported elimination half-life was under three hours, and exposure varied by formulation.^[14]

These pharmacokinetic findings help explain why formulation and study design matter. They do not independently establish how often a research preparation should be administered.

The use of Thymosin Alpha-1 has been investigated in chronic hepatitis B, chronic hepatitis C, sepsis, viral disease, immunodeficiency, vaccine-adjuvant research, and as an adjunct to cancer therapy. Reviews also discuss exploratory work in lung cancer, breast cancer, and autoimmune diseases. These are research categories, not proof that peptide therapy improves any individual condition.^[1][2][5]

The effect of Thymosin Alpha-1 varies across trials. Some older treatment-of-hepatitis-B studies reported delayed virologic responses, while other investigations produced uncertain or neutral results. Combination therapy, patient selection, disease severity, and the study endpoint all influence interpretation.^[4][15]

Thymosin Alpha-1 does not function as a conventional direct antiviral drug. Its proposed actions involve host immune pathways, so evidence about an immune marker or response rate should not be presented as a guaranteed clinical benefit.^[2][6]

• Mixed outcomes: Reviews and smaller studies report signals in selected populations, while a large phase 3 sepsis trial was neutral for its primary mortality outcome.^[3][12]
• Condition-specific evidence: Hepatitis, COVID-19, liver failure, sepsis, and cancer-adjunct studies should not be pooled into a single universal dosage claim.^[2][16][17]
• Formulation differences: Pharmacokinetic exposure can differ among formulations, limiting direct comparison across products.^[14]
• Research context: A concentration calculation can be mathematically correct without proving safety, efficacy, or suitability for a person.

Reported adverse events in published trials are often described as mild or similar to control groups, with injection-site reactions among the practical concerns. However, safety evidence varies by formulation, route, population, duration, and concomitant treatment.^[5][7]

The FDA has stated that compounded Thymosin Alpha-1 may present immunogenicity and peptide-impurity concerns and that available safety information is inadequate to fully characterize the risks of proposed compounded products. That warning is distinct from the results of trials using characterized study products.^[18]

This page is for research and educational interpretation. It is not medical advice and does not establish a treatment recommendation.

For a study or clinician-directed subcutaneous procedure, the exact preparation, device, route, and site instructions take priority. General references emphasize hand hygiene, a new sterile syringe, a clean vial stopper and skin, appropriate subcutaneous tissue, and systematic site rotation.^[9][10][11]

The page’s 9-unit and 15-unit markings are volume conversions for the stated 3.33 mg/mL concentration. They should be recalculated if the vial strength or final liquid volume changes.

Confirm the product identity, labeled strength, lot documentation, and handling instructions before using any vial in laboratory work. The Pure Lab Peptides product page is included for the 10 mg vial and batch-documentation context; it is not used as scientific evidence for clinical efficacy or a dosing claim.^[13]

What is the concentration after adding 3 mL to a 10 mg vial?

The concentration is 10 mg ÷ 3.0 mL, or approximately 3.33 mg/mL. On a U-100 syringe, 1 unit is 0.01 mL, which equals approximately 33.3 mcg at that concentration.

Is a 10 mg vial itself a 10 mg dose?

No. Ten milligrams describes the total peptide mass in the vial. An amount per administration is a separate value determined from the concentration and measured volume.

Does Thymosin Alpha-1 have one standard research protocol?

No. Human trials have used different schedules for different conditions, and study regimens cannot be generalized into one validated protocol.^[4][12][17]

What does “Thymosin Alpha-1 dosage when sick” mean in the evidence?

That search phrase spans very different illnesses and evidence types. Controlled research must be interpreted by the specific diagnosis, population, formulation, route, and outcome; it does not support a self-directed “when sick” amount.^[2][12]

How does the 10 mg page differ from the 5 mg page?

The vial contains twice the peptide mass. If both vials were prepared to the same final concentration, their syringe math would match; if their final volumes or concentrations differ, every mL and U-100 conversion must be recalculated.

The dosage chart retains the page’s established educational calculation schedule. Published study schedules differ and are summarized only to show the limits of the evidence. This information is not medical advice, a standard of care, or proof of safety or efficacy.

• 1
  World Journal of Virology — Dominari et al. (2020): comprehensive review of Thymosin Alpha-1 mechanisms and clinical research

  View Source
• 2
  Molecules — Tao et al. (2023): mechanisms and clinical research in viral infectious diseases

  View Source
• 3
  Inflammopharmacology — Soeroto et al. (2023): systematic review and meta-analysis of Tα1 in COVID-19

  View Source
• 4
  Hepatology — Chien et al. (1998): randomized chronic hepatitis B trial using 1.6 mg subcutaneously twice weekly

  View Source
• 5
  Annals of the New York Academy of Sciences — Garaci et al. (2007): biological activities and clinical applications review

  View Source
• 6
  Clinical Immunology — Romani et al. (2007): immunomodulatory mechanisms of Thymosin Alpha-1

  View Source
• 7
  FDA Pharmacy Compounding Advisory Committee — December 2024 Thymosin Alpha-1 briefing and safety review

  View Source
• 8
  Hospital Pharmacy — Jordan et al.: accuracy and precision considerations when measuring small liquid volumes with syringes

  View Source
• 9
  Centers for Disease Control and Prevention — general subcutaneous route, needle, and site guidance in vaccine administration

  View Source
• 10
  Johns Hopkins Arthritis Center — patient guidance for subcutaneous injection site selection and rotation

  View Source
• 11
  NCBI Bookshelf — injection preparation, asepsis, site rotation, and administration practices

  View Source
• 12
  BMJ — Wu et al. (2025): multicenter, double-blind, placebo-controlled TESTS phase 3 sepsis trial

  View Source
• 13
  Pure Lab Peptides — Thymosin Alpha-1 10 mg vial and batch-documentation context

  View Source
• 14
  International Journal of Clinical Pharmacology and Therapeutics — pharmacokinetics of three subcutaneous Thymosin Alpha-1 formulations in healthy volunteers

  View Source
• 15
  Journal of Gastroenterology — phase 3 multicenter placebo-controlled chronic hepatitis B trial

  View Source
• 16
  International Immunopharmacology — systematic review and meta-analysis of adult COVID-19 clinical outcomes

  View Source
• 17
  Journal of Viral Hepatitis — randomized controlled trial in hepatitis B virus-related acute-on-chronic liver failure

  View Source
• 18
  U.S. Food and Drug Administration — significant safety-risk concerns for compounded Thymosin Alpha-1

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.